Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
Durie
B G
BG
University of Arizona Cancer Center.
Crowley
J
J
Coltman
C A
CA
Chapman
R A
RA
Balcerzk
S P
SP
Bonnet
J D
JD
Lipschitz
D A
DA
Stephens
R L
RL
Cheson
B D
BD
D000368:Aged; D000369:Aged, 80 and over; D000873:Anthracenes / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D014410:Tumor Stem Cell Assay
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene